Anavex Life Sciences Corp (AVXL)

[rx7171]

So is the slightly missed ADL during the 48 weeks countered successfully by the highly statistically met ADL in the OLE?

Knowing ADL sensitivity in a short early Alzheimers trial has become recognized as problematic the data from a longer trial period should take precedence.

The question however is will the OLE data be given the same degree of credibility as the 48 week trial data since it is unblinded and subject to placebo effect?
Due to the total trial length including the OLE I believe the positive ADL data will be accepted as an accurate reflection of a true disease modifying effect.